With the development of aliskiren, blockade of the renin–angiotensin–aldosterone system
(RAAS) at the level of the interaction of renin with a substrate has become a clinical reality …

A review of six clinical trials of aliskiren involving> 5,000 patients with mild to moderate
hypertension indicated that this first of a new class of orally active antihypertensive drugs is …

BACKGROUND: Despite the availability of many effective, well-tolerated drugs, a significant
proportion of treated hypertensive patients still have uncontrolled high blood pressure (BP) …

Aliskiren is the first orally active inhibitor of renin to be approved for clinical use as an
antihypertensive agent. The development program has established that at the licensed …

J Clin Hypertens (Greenwich). 2010; 12: 765‐775.© 2010 Wiley Periodicals, Inc. While the
safety of renin‐angiotensin system (RAS)–blocking drugs such as angiotensin‐converting …

Abstract The Joint National Committee and the World Health Organization are in agreement
that hypertension in most patients who are treated is controlled inadequately and that rates …

Use of drugs that inhibit the renin-angiotensin system is an effective way to intervene in the
pathogenesis of cardiovascular and renal disorders. The idea of blocking the renin system at …

Aliskiren is the first member of the new class of orally active direct renin inhibitors to receive
approval from the United States Food and Drug Administration for the treatment of …

Fifty years ago, investigators identified renin inhibition as the preferred pharmacologic
approach to blockade of the renin–angiotensin system. Renin is a monospecific enzyme that …

The first evidence of the existence of renin was presented over 100 years ago. However, the
importance of renin and the renin–angiotensin system in the pathogenesis of cardiovascular …